Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's ...

Contributed by Tai-ping Sun; received May 6, 2025; accepted July 7, 2025; reviewed by Huilin Li, Makoto Matsuoka, and Claus Schwechheimer ...

ANAVEX3-71-002 trial achieved its primary endpoint demonstrating safety and tolerability in both male and female adultsOral ANAVEX®3-71 tablet ...

Copyright: © 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies. The management of moderate ...

Bristol Myers Squibb (BMS) plans to launch schizophrenia drug Cobenfy in the UK next year at a price matching its U.S. list price, it said on Monday.

Karuna Therapeutics and Bristol Myers Squibb are winners of the 2025 Gizmodo Science Fair for their research and development of Cobenfy (xanomeline-trospium), the first truly novel medication for ...

Anti-obesity drugs such as semaglutide (Ozempic, Wegovy) are also promising for the treatment of alcohol use disorder and alcohol-associated liver disease, as growing evidence suggests they reduce the ...

A dataset named CARDIOPEG has been uploaded to the Dryad website. It contains all the individual experiments used for the figures in the article.

VIENNA — Adults with obesity but without diabetes who took the investigational, oral GLP-1 receptor agonist orforglipron for 72 weeks lost significantly more weight than those on placebo, according to ...

Background: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used to improve glycemic control and induce weight loss in individuals with type 2 diabetes (T2D), yet treatment responses ...